Expression of hypoxia-inducible factor-1α and the protein products of its target genes in diabetic fibrovascular epiretinal membranes

British Journal of Ophthalmology

Volumn 91, Issue 6, 2007, Pages 822-826

  El Asrar, Ahmed M Abu ^a,b   Missotten, Luc ^c   Geboes, Karel ^c  

^a KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; CD34 ANTIGEN; CD45 ANTIGEN; ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; PIGMENT EPITHELIUM DERIVED FACTOR; POLYCLONAL ANTIBODY; VASCULOTROPIN;

ARTICLE; BLOOD VESSEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DIABETIC RETINOPATHY; EPIRETINAL MEMBRANE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LEUKOCYTE; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

ANGIOPOIETIN-2; ANTIGENS, CD34; CELL DIVISION; DIABETIC RETINOPATHY; EPIRETINAL MEMBRANE; ERYTHROPOIETIN; EYE PROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; NERVE GROWTH FACTORS; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34249814615     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.109876     Document Type: Article

References (45)

1. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:C1358-66.
2. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-8.
3. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
4. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-50.
5. Spranger J, Osterhoff M, Reimann M, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001;50:2641-5.
6. Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004;18:1450-2.
7. 2 tension. Am J Physiol 1996;271:C1172-80.
8. 2 tension. Proc Natl Acad Sci USA, 1995;92:5510-14.
9. Huang LE, Gu J, Schau M, et al. Regulation of hypoxia-inducible factor 1 alpha is mediated by an Gvdependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA, 1998;95:7987-92.
10. Hirota K, Semenza GL. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006;59:15-26.
11. Bunn HF, Gu J, Huang LE, et al. Erythropoietin: a model system for studying oxygen-dependent gene regulation. J Exp Biol 1998;201:1197-201.
12. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
13. Yamakawa M, Liu LX, Date T, et al. Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors. Circ Res 2003;93:664-73.
14. Jelkmann W. Molecular biology of erythropoietin. Int Med 2004;43:649-59.
15. Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64:326-33.
16. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782-92.
17. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature (London), 2000;407:242-8.
18. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci USA, 2002;99:11205-10.
19. Giatromanolaki A, Sivridis E, Simopoulos C, et al. Hypoxia inducible factors 1 alpha and 2 alpha are associated with VEGF expression and angiogenesis in gall bladder carcinomas. J Surg Oncol 2006;94:242-7.
20. Sivridis E, Giatromanolaki A, Gatter KC, et al. Association of hypoxia-inducible factors 1 alpha and 2 alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma. Cancer 2002;95:1055-63.
21. Kuwai T, Kitadai Y, Tanaka S, et al. Expression of hypoxia-inducible-1 alpha is associated with tumor vascularization in human colorectal carcinoma. Int J Cancer 2003;105:176-81.
22. Theodoropoulos VE, Lazaris ACH, Sofras F, et al. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol 2004;46:200-8.
23. Jung F, Haendeler J, Hofmann J, et al. Hypoxic induction of the hypoxia-inducible factor is mediated via the adaptor protein Shc in endothelial cells. Circ Res 2002;91:38-45.
24. Nilsson J, Shibuya M, Wennstrom S. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res 2004;299:476-85.
25. Yu AY, Frid MG, Shimoda LA, et al. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Lung Cell Mol Physiol 1998;19:L818-26.
26. Chavez JC, Almhanna K, Berti-Mattera LN. Transient expression of hypoxia-inducible factor-1 alpha and target genes in peripheral nerves from diabetic rats. Neurosci Lett 2005;374:179-82.
27. Mandriota SJ, Pyke C, Di Sanza C, et al. Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia. Am J Pathol 2000;156:2077-88.
28. Oh H, Takagi H, Suzuma K, et al. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999;274:15732-9.
29. Zhu Y, Lee C, Shen F, et al. Angiopoietin-2 facilitates vascular endothelial growth factor-induced angiogenesis in the mature mouse brain. Stroke 2005;36:1533-7.
30. Tanaka F, Ishikawa S, Yanagihara K, et al. Expression of angiopoietins and its clinical significance in non-small cell lung cancer. Cancer Res 2002;62:7124-9.
31. Tsutsui S, Inoue H, Yasuda K, et al. Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. Breast Cancer Res Treat 2006;98:261-6.
32. Zhang L, Yang N, Park J-W, et al. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003;63:3403-12.
33. Umeda N, Ozaki H, Yayashi H, et al. Colocalization of the Tie 2, angiopoietin-2 and vascular endothelial growth factor in fibrovascular membrane from patients with retinopathy of prematurity. Ophthalmic Res 2003;35:217-23.
34. Takagi H, Koyama S, Seike H, et al. Potential role of the angiopoietin/tie 2 system in ischemia-induced retinal neovascularization. Invest J Ophthalmol Vis Sci 2003;44:393-402.
35. Ohashi H, Takagi H, Koyama S, et al. Alterations in expression of angiopoietins and the tie-2 receptor in the retina of streptozotocin induced diabetic rats. Mol Vision 2004;10:608-17.
36. Watanabe D, Suzuma K, Suzuma I, et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am J Ophthalmol 2005;139:476- 81.
37. Lemieux C, Maliba R, Favier J, et al. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood 2005;105:1523-30.
38. Joussen AM, Poulaki V, Qin W, et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 2002;160:501-9.
39. Joussen AM, Poulaki V, Tsujikawa A, et al. Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 2002;160:1683-93.
40. Nambu H, Umda N, Kachi S, et al. Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization. J Cell Physiol 2005;204:227-35.
41. Nambu H, Nambu R, Oshima Y, et al. Angiopoietinl inhibits ocular neovascularization and breakdown of the blood-retinal barrier. Gene Ther 2004;11:865-73.
42. Gao G, Li Y, Zhang D, et al. Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization. FEBS Lett 2001;489:270-6.
43. Katsura Y, Okano T, Matsuno K, et al. Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetes Care 2005;28:2252-4.
44. Inomata Y, Hirata A, Takahashi E, et al. Elevated erythropoietin in vitreous with ischemic retinal diseases. Neuroreport 2004;15:877-9.
45. Jones DT, Harris AL. Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol Cancer Ther 2006;5:2193-202.